Dasiglucagon
Dasiglucagon, sold under the brand name Zegalogue, is a medication used to treat severe hypoglycemia in people with diabetes.The most common side effects include nausea, vomiting, headache, diarrhea, and injection site pain.Dasiglucagon was approved for medical use in the United States in March 2021. It was designated an orphan drug in August 2017.

Medical uses
Dasiglucagon is indicated for the treatment of severe hypoglycemia in people aged six years of age and older with diabetes.

Contraindications
Dasiglucagon is contraindicated in people with pheochromocytoma or insulinoma.

References
External links
"Dasiglucagon". Drug Information Portal. U.S. National Library of Medicine.
Clinical trial number NCT03378635 for "A Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Type 1 Diabetes Subjects" at ClinicalTrials.gov
Clinical trial number NCT03688711 for "Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM" at ClinicalTrials.gov
Clinical trial number NCT03667053 for "Trial to Confirm the Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in T1DM Children" at ClinicalTrials.gov